VEGFA and metastatic colorectal cancer: Owing to the extensive research on VEGF, the VEGFA (vascular endothelial growth factor A) inhibitor bevacizumab was authorized by the Food and Drug Administration for the first-line treatment of metastatic colorectal cancer in 2004 [23, 24].